Skip to Content
Merck

55514

BioStab Antibody Stabilizer

Synonym(s):

Antibody Stabilizer BioStab

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

NACRES:
NA.25
UNSPSC Code:
12352204
Technique(s):
HPLC: suitable
Species reactivity:
-
Application:
HPLC
Citations:
6
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


technique(s)

HPLC: suitable

Quality Level

impurities

DNases, none detected, RNases, none detected, phosphatases, none detected, proteases, none detected

suitability

corresponds for identity (HPLC)

storage temp.

2-8°C

Application

Antibodies can be protected from degradation effects using BioStab Antibody Stabilizer. The addition of BioStab Antibody Stabilizer increases life-time and the coating rates of the antibodies. BioStab Antibody Stabilizer can be used in ELISA, Western Blotting, Immunohistochemistry and any other applications which require marker or biotinylated antibodies. This stabilizer contains a minimum amount of a surfactant.


Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library


Related Content


Jarem Edwards et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 25(11), 3247-3258 (2019-02-20)
Immunotherapies targeting costimulating and coinhibitory checkpoint receptors beyond PD-1 and CTLA-4 have entered clinical trials. Little is known about the relative abundance, coexpression, and immune cells enriched for each specific drug target, limiting understanding of the biological basis of potential
Tim Serno et al.
Advanced drug delivery reviews, 63(13), 1086-1106 (2011-09-13)
Aggregation is arguably the biggest challenge for the development of stable formulations and robust manufacturing processes of therapeutic proteins. In search of novel excipients inhibiting protein aggregation, cyclodextrins and their derivatives have been under examination for use in parenteral protein
Eduardo P Melo et al.
Current protein & peptide science, 11(8), 744-751 (2011-01-18)
Biomedical applications of osmolytes, including stabilization of protein-based pharmaceutics, preservation of living biological material and potential therapeutic prescription in vivo, are intimately related to the fact that osmolytes favour the native structure of proteins. The shift towards the native structure



Global Trade Item Number

SKUGTIN
45407-250MG04061832340333
55514-250ML-F04061837727863